Loading…
Adagene Inc. is projected to rise to $5.85 by 2027, a +46% move from its current price of $4.00. ADAG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.86 | $4.00 | $4.15 | +0.06% |
| May 30 | $3.80 | $4.00 | $4.22 | +0.12% |
| May 31 | $3.76 | $4.01 | $4.27 | +0.18% |
| Jun 1 | $3.73 | $4.01 | $4.32 | +0.24% |
| Jun 2 | $3.70 | $4.01 | $4.36 | +0.30% |
| Jun 3 | $3.67 | $4.01 | $4.39 | +0.36% |
| Jun 4 | $3.64 | $4.02 | $4.43 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.64 | $4.02 | $4.43 | +0.42% |
| Week 2 | $3.52 | $4.03 | $4.63 | +0.85% |
| Week 3 | $3.42 | $4.05 | $4.80 | +1.28% |
| Week 4 | $3.35 | $4.07 | $4.94 | +1.71% |
| Week 5 | $3.29 | $4.09 | $5.08 | +2.14% |
| Week 6 | $3.23 | $4.10 | $5.21 | +2.58% |
| Week 7 | $3.18 | $4.12 | $5.33 | +3.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adagene Inc. is a clinical stage biotechnology company that engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Incorporated in 2011 and headquartered in Suzhou, China, Adagene focuses on oncology therapies through a diverse pipeline of antibody programs.
Its lead product candidate is ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody; ADG206, in phase 1 clinical development; ADG104, anti-PD-L1 monoclonal antibody in phase 2; and ADG125, a novel anti-CSF-1R mAb in Phase 2. Additional programs include ADG138 (preclinical), ADG152 (preclinical), ADG153 (preclinical), and CD28 T-cell engagers, among others, reflecting a broad oncology-focused portfolio.
Adagene Inc. (ADAG) current price is $3.75. The market cap stands at $247.77M and the stock is ranked 3678.
As of now, the asset trades with a relatively small-cap profile in the healthcare space, and its price outlook is bullish over the longer horizon according to the year-by-year forecast data.
The forecast shows a rising trajectory for the average price across years: 2026 avg $3.75, 2027 avg $5.61, 2028 avg $7.57, 2029 avg $9.21, 2030 avg $10.37, 2031 avg $11.83, 2032 avg $13.15, 2033 avg $13.43, 2034 avg $17.91, 2035 avg $23.50, 2040 avg $34.52, and 2050 avg $86.71, with corresponding ROI values moving from 0 to progressively higher levels in later years.
A major floor 57.7% below — a decisive break under it would weaken the trend.
The nearest floor, 15.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 15.3% above — clearing it would confirm fresh momentum.
Key ADAG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADAG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.74 | Buy | $3.78 | Buy |
| MA 10 | $3.64 | Buy | $3.70 | Buy |
| MA 20 | $3.65 | Buy | $3.68 | Buy |
| MA 50 | $3.79 | Buy | $3.61 | Buy |
| MA 100 | $3.24 | Buy | $3.29 | Buy |
| MA 200 | $2.59 | Buy | $2.86 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.71 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 209.99 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 8.40 | Buy |
| Bollinger %B (20,2) | 1.10 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 70.82 | Sell |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 3.89 | Buy |
| ADX (14) | 10.12 | Neutral |
| ATR (14) | 0.11 | Info |
30-day technical picture shows a neutral-to-bullish tilt in the near term.
RSI14 is 50, indicating neither overbought nor oversold momentum. The short-term moving averages point toward positive bias with SMA50 at $3.80 and SMA200 at $2.57.
Near-term support sits at $3.39 and resistance at $3.97, framing a modest upside if the price can sustain above current levels. The 30-day price range runs from $2.96 to $4.75, and annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.53 | $4.00 | $5.50 | 0% | Neutral | |
| $4.48 | $5.85 | $8.17 | +46% | Bullish | |
| $5.86 | $7.95 | $11.62 | +99% | Bullish | |
| $6.98 | $9.77 | $14.81 | +144% | Bullish | |
| $7.49 | $10.79 | $16.85 | +170% | Bullish | |
| $8.34 | $12.34 | $19.80 | +209% | Bullish | |
| $9.11 | $13.82 | $22.70 | +246% | Bullish | |
| $8.86 | $13.77 | $23.09 | +244% | Bullish | |
| $11.57 | $18.38 | $31.44 | +360% | Bullish | |
| $15.01 | $24.38 | $42.44 | +509% | Bullish | |
| $19.70 | $35.40 | $66.44 | +785% | Bullish | |
| $41.28 | $89.16 | $186.37 | +21.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.53 | $4.00 | $4.71 | +0.00% |
| June 2026 | $3.40 | $4.02 | $4.89 | +0.55% |
| July 2026 | $3.53 | $4.23 | $5.24 | +5.10% |
| August 2026 | $3.50 | $4.23 | $5.31 | +0.06% |
| September 2026 | $3.32 | $4.04 | $5.13 | -4.44% |
| October 2026 | $3.34 | $4.09 | $5.25 | +1.16% |
| November 2026 | $3.46 | $4.26 | $5.52 | +4.28% |
| December 2026 | $3.40 | $4.21 | $5.50 | -1.22% |
Click any year to see its month-by-month ADAG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADAG price prediction for 2026 points to an average of $4.00 (low $1.53, high $5.50) — a potential gain of 0% on today's $4.00. Price action looks broadly range-bound.
In 2027, ADAG is projected to trade between $4.48 and $8.17, averaging $5.85 — a potential gain of +46% from today's $4.00. That is up +46% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Adagene Inc.'s 2028 outlook centres on $7.95, within a $5.86 to $11.62 range. That is up +36% on the projected 2027 average. That marks a +99% change versus current levels. Momentum favours further upside here.
By 2029, ADAG could reach as high as $14.81, with a base case around $9.77 and support toward $6.98 — roughly +144% from $4.00. Buyers look set to stay in control over this stretch.
Expect ADAG to range from $7.49 to $16.85 through 2030. The $10.79 average target implies a +170% move from current prices. That is up +10% on the projected 2029 average. Momentum favours further upside here.
The ADAG price prediction for 2031 points to an average of $12.34 (low $8.34, high $19.80) — a potential gain of +209% on today's $4.00. Buyers look set to stay in control over this stretch.
In 2032, ADAG is projected to trade between $9.11 and $22.70, averaging $13.82 — a potential gain of +246% from today's $4.00. That is up +12% on the projected 2031 average. Momentum favours further upside here.
Adagene Inc.'s 2033 outlook centres on $13.77, within a $8.86 to $23.09 range. That is 0% versus the projected 2032 average. That marks a +244% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADAG could reach as high as $31.44, with a base case around $18.38 and support toward $11.57 — roughly +360% from $4.00. Momentum favours further upside here.
Expect ADAG to range from $15.01 to $42.44 through 2035. The $24.38 average target implies a +509% move from current prices. That is up +33% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADAG price prediction for 2040 points to an average of $35.40 (low $19.70, high $66.44) — a potential gain of +785% on today's $4.00. Momentum favours further upside here.
In 2050, ADAG is projected to trade between $41.28 and $186.37, averaging $89.16 — a potential gain of +21.3x from today's $4.00. That is up +152% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADAG today (≈ 250 ADAG) could be worth
$22,290.78
+$21,290.78 (+2129%) by 2050 · US Dollar
Based on the average projected ADAG price of $89.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADAGwould be worth at today's price.
$1,000 invested in ADAG on May 27, 2025 (≈ 524.934391 ADAG) would be worth
$2,099.74
+$1,099.74 (+110.0%) today · 2.10× · US Dollar
Based on a ADAG entry price of $1.9 vs. today's $4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.45 | $1,159.42 | +15.9% |
| 1 month ago | $3.56 | $1,123.6 | +12.4% |
| 3 months ago | $3.11 | $1,288.24 | +28.8% |
| 6 months ago | $2.01 | $1,990.05 | +99.0% |
| 1 year ago | $1.9 | $2,099.74 | +110.0% |
| All time (5.0y) ago | $13.99 | $285.92 | -71.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADAG forecast.
Our base-case forecast reaches $8.00 around 2029.
Implied market cap at $8.00: $528.58M
The multi-year forecast portrays a bullish outlook with a steady rise in the average price and growing potential returns through 2050.
By 2030, the forecast shows an avg of $10.37 with an ROI of 176.6 and a bullish sentiment. By 2040, the avg rises to $34.52 with an ROI of 820.5, and by 2050 the avg is $86.71 with an ROI of 2212.1, underscoring a strong longer-term upside if the trajectory materializes.
These figures reflect a broad, asset-wide elevation in valuation over time, driven by a diverse oncology-focused pipeline that includes ADG126, ADG116, ADG206, ADG104, ADG125 and related programs, plus preclinical assets. Risks include the inherent uncertainty of clinical-stage development and market dynamics, and the forecasts are estimates, not guarantees.
Tap a question to reveal the answer.
2030 — avg $10.37; min $7.24; max $16.10; ROI 176.6.
Forecast data show bullish sentiment from 2027 onward with rising avg prices (e.g., 2027 avg $5.61, 2028 avg $7.57, 2030 avg $10.37, up to 2050 avg $86.71) and positive ROI figures, but these are estimates and not guarantees.
Yes. The 2040 forecast shows a max of $64.17 and an average of $34.52, indicating that a $50 level is within the projected range.
Current price is $3.75 and market cap is $247.77M, with a rank of 3678.
2050 — avg $86.71; min $41.03; max $179.22; ROI 2212.1; sentiment BULLISH.
Adagene Inc. Community Discussion
0Share your Adagene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.